Indeed, the results of this study highlighted, for the first time, that inhibition of DPP-4 using linagliptin (at 1 h after CLP) attenuates the cardiac dysfunction associated with T2DM/CLP-sepsis and this was associated with, or occurred as a result of, an inhibition of NF-κB activation and preservation of Akt pathway activation in the heart. Here, AKT1 is linked to type 2 diabetes mellitus.